Status:
COMPLETED
Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations
Lead Sponsor:
Respiratory Effectiveness Group
Collaborating Sponsors:
Boehringer Ingelheim
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Brief Summary
This is an international, mulitcentre, observational, prospective study into Peak Inspiratory Flow in COPD patients that aims to: A) Determine the prevalence of suboptimal Peak Inspiratory Flow (PIF) ...
Eligibility Criteria
Inclusion
- Spirometry-defined COPD (i.e. post-bronchodilator FEV1/FVC\<0.7)
- Age ≥40 years
- Smokers or ex-smokers of at least 10 pack-years
- Clinically stable COPD (no exacerbations in the last 4 weeks)
- Capable of performing serial lung function tests
- Prescribed inhaled medication for at least 6 months
Exclusion
- Occurrence of an COPD exacerbation during the previous 4 weeks
- Have any concomitant chronic respiratory condition other than asthma or bronchiectasis (e.g. cystic fibrosis, lung fibrosis, tuberculosis)
- Are unable to understand the instructions of the study or to fill the questionnaires
- Are unwilling to sign the informed consent
- Are participating in a clinical trial
Key Trial Info
Start Date :
December 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 25 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04360226
Start Date
December 14 2020
End Date
January 25 2024
Last Update
April 10 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Sassari
Sassari, Italy
2
Mater Dei Hospital
Valletta, Malta
3
Changi General Hospital
Singapore, Singapore
4
Singapore General Hospital
Singapore, Singapore